CD33 and leukemia: Different from approaches aimed at the removal or truncation of the target molecule, which can be applied only to dispensable genes (such as CD33 and CLEC12A (also known as CLL-1)), epitope engineering enables the targeting of genes that are essential for leukaemia survival regardless of their function in healthy haematopoiesis.